Technology & Innovation

Oxford Cannabinoid Technologies expanding research into cancer after identifying potential new treatment

Published by
Giles Gwinnett

Oxford Cannabinoid Technologies Holdings (OTCP), which is developing cannabinoid medicines, revealed it was expanding its research into cancer, having identified a potential "first in class" immunotherapy agent to treat solid tumours.

This has arisen due to work on the firm's cannabinoid library of almost 500 derivatives in its Programme 4 and further demonstrated the value of the company's exclusive licence agreement with Canopy Growth Corp, OTCP said.

READ MORE: Oxford Cannabinoid Technologies appoint new CEO and renews licence

"Attention will now focus on further in vitro and in vivo studies to highlight the full potential of this lead-candidate. This will be followed by a safety-pharmacology assessment before final candidate selection, likely during 2024," the company added.

Clarissa Sowemimo-Coker, CEO of OCTP, told investors: "There is an urgent need for new cancer medications. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics.

"Although we're at an early stage, this is exciting news for the company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research & development and we are extremely excited to have identified a possible candidate that could have a significant impact on many peoples' lives."

The company's programme 4 is targeting a share of a market of therapies against solid tumours projected to be worth US$532 million by 2032.

The pharmaceutical company is developing prescription cannabinoid medicines and targeting the multi-billion US dollar global pain market.

It currently has a portfolio of four drug development programmes. Its lead compound OCT461201 will initially target neuropathic and visceral pain and Phase 1 clinical trial results are expected in the third quarter of 2023.

Visit Hampshire Biz News for bright, upbeat and positive business news from the county

Giles Gwinnett

Giles Gwinnett is a writer at The Business Magazine. He has been a journalist for more than 20 years and covered a vast array of topics at a range of media settings - in print and online. After his NCTJ newspaper training, he became a reporter in Hampshire before moving to a news agency in Gloucestershire. In recent years, he has been covering the financial markets along with company news for an investor-focused web portal. His many interests include politics, energy and the environment. He lives in Dorset.

Recent Posts

Four features of the Tech Start Up of the Year

Start Ups are one of the most exciting parts of a thriving tech sector, and…

1 hour ago

Do you know the Young Property Person of the Year?

Though every category at the Thames Valley Property Awards sees a diverse range of entries…

2 hours ago

Baking and British Sign Language courses booming at Warwickshire college

New courses in baking and British Sign Language (BSL) at Royal Leamington Spa College have…

9 hours ago

Bristol’s 9Trees picks up national title at FSB Celebrating Small Business Awards

The Federation of Small Businesses (FSB) has awarded the Micro Business Award to a leading…

9 hours ago

Green light for Allsee Technologies’ Birmingham HQ set to create 150 jobs

Allsee Technologies’ proposed landmark office headquarters and digital technology centre at Longbridge Business Park in…

9 hours ago

Bristol Rovers Community Trust gets show on the road with new luxury minibus

A Bristol community charity has moved into vehicle purchasing for the first time with the…

9 hours ago